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Abstract
In women with human epidermal growth factor 2 (HER2)-positive breast cancer, improved 
control of systemic disease with new therapies has unmasked brain metastases that historically 
would have remained clinically silent. Efficacy of therapeutic agents against brain metastases is 
limited by their inability to permeate the blood-brain and blood-tumor barriers (BBB and BTB) 
in therapeutic amounts. Here, we investigate the potential of mucic acid-based, targeted 
nanoparticles designed to transcytose the BBB/BTB to deliver a small molecule drug, 
camptothecin (CPT), and therapeutic antibody, Herceptin, to brain metastases in mice. Treatment 
with BBB-targeted combination CPT/Herceptin nanoparticles significantly inhibits tumor growth 
compared to free CPT/Herceptin and BBB-targeted nanoparticles carrying CPT alone. Though 
not as efficacious, BBB-targeted nanoparticles carrying only Herceptin also elicit considerable 
antitumor activity. These results demonstrate the potential of the targeted nanoparticle system for 
the delivery of antibody alone or in combination with other drugs across the BBB/BTB to 
improve the therapeutic outcome.
Keywords
polymeric nanoparticle; blood-brain barrier; systemic delivery; Herceptin; camptothecin
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Communication
Brain metastases of breast cancer are presenting an increasing challenge in the clinic. 
Historically, brain metastases were not a major problem for most breast cancer patients because 
they usually developed late in the course of disease, and lack of systemic control limited 
survival.1,2 However, new therapies have improved clinical outcomes in some subsets of patients, 
and brain progression has become a more significant threat to long-term survival. 3,4
The risk of brain metastasis varies considerably with breast cancer subtype.5,6 Human epidermal 
growth factor 2 (HER2)-positive breast cancers have been shown to metastasize to the brain at 
higher rates than other breast cancer subtypes (ca. 25 to 50%).5,7,8 Although HER2-targeted 
therapies can effectively control extracranial disease, they have limited distribution to brain 
metastases and demonstrate poor efficacy in this setting.9–11 Current therapeutic options such as 
surgery, radiation and chemotherapy are considered palliative, and rarely provide a significant 
increase in survival.6,12–14 
Delivery of HER2-inhibitors and most chemotherapeutics to brain metastases is limited by poor 
drug penetration across the blood-brain barrier (BBB),13,14 a selective cellular barrier that acts as 
a regulator for the movement of molecules into and out of the brain.15 The tumor 
microvasculature associated with brain metastases, often referred to as the blood-tumor barrier 
(BTB), has increased passive permeability relative to the intact BBB16; however, the loss in 
barrier integrity is limited and highly variable from tumor to tumor and even within the 
metastatic lesion.16–18 Many drugs commonly used to treat HER2-positive breast cancer are 
unable to reach therapeutic concentrations in the brain,10,16 and circumventing the BBB and BTB 
remains a major obstacle in effective treatment of brain metastases.
There has been significant interest in engineering nanoparticles and other nanoscale or polymeric 
drug formulations to enhance the delivery of therapeutic agents to the brain following systemic 
administration.13,19–22 The use of endogenous transport mechanisms at the BBB such as receptor-
mediated transcytosis (RMT) has emerged as a promising approach to shuttle a variety of 
payloads across the BBB.23–25 In particular, transferrin receptor (TfR) has been one of the 
primary targets investigated for RMT because of its high expression on the blood side of the 
BBB endothelium.26 Recently, we investigated the brain uptake and efficacy of TfR-targeted 
therapeutic nanoparticles designed to transcytose the BBB/BTB. Transferrin (Tf) was attached to 
nanoparticles consisting of a mucic acid polymer (MAP) conjugate of camptothecin (CPT), 
denoted MAP-CPT, through a pH-dependent, boronic acid-diol complexation to the vicinal diols 
contained within the mucic acid portions of the polymer.27 With this acid-cleavable targeting 
strategy,28 nanoparticles retain high avidity to TfR on the blood side of the BBB to enable 
practical, systemic dosing, yet release the targeting agents upon acidification during transcytosis 
to allow their release into the brain. We demonstrated that these targeted nanoparticles, 
administered systemically, were capable of delivering CPT to HER2-positive breast cancer brain 
metastases in mice and eliciting a considerable antitumor response.27 
We hypothesized that TfR-targeted nanoparticles carrying more potent therapeutic agents would 
reveal even greater tumor size reductions.27 Here, we assess whether this delivery system can be 
used to shuttle an anti-HER2 monoclonal antibody, Herceptin, alone or in combination with a 
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CPT payload, across the BBB to achieve enhanced antitumor activity over the previously 
reported efficacy of CPT alone (Figure 1).
Figure 1. Proposed mechanism for delivery of drug and antibody combination to brain 
metastases using acid-cleavable targeting ligands. At extracellular pH 7.4, Tf ligands and 
Herceptin remain bound to the diols on the nanoparticle surface. After endocytosis, rapid 
acidification of the endosome to pH 5.5 triggers their dissociation from the nanoparticle core, 
allowing free diffusion into the brain once transcytosis is complete.
MAP-CPT polymer-drug conjugate was prepared as previously described (Supporting 
Information Figure S1).27 Properties of the material used in this study are provided in Supporting 
Information Table S1. MAP-CPT conjugate was then dialyzed against water to form 
nanoparticles with hydrophobic CPT molecules preferentially clustered in the core and mucic 
acid diols on the surface (Figure 2A).
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Figure 2. Single-agent or combination drug and antibody nanoparticle delivery systems. 
Preparation of TfR-targeted combination CPT/Herceptin nanoparticle (A), TfR-targeted CPT 
nanoparticle (B) and TfR-targeted Herceptin nanoparticle (C) formulations. w ~ 82 for 3.4kDa 
PEG; x ~ 20 for material used in this study; y ~ 84 for 3.5kDa PEG; z ~ 120 for 5kDa PEG. 
3-carboxy-5-nitrophenyl boronic acid (nitroPBA)-Herceptin and Tf conjugates were synthesized 
in a manner similar to that reported previously.27 Briefly, nitroPBA was added to 3.5-kDa 
polyethylene glycol (PEG), followed by conjugation of the polymer to Herceptin using 
EDC/NHS chemistry (Supporting Information Figure S2A). A Tf-containing analog was 
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prepared using 5-kDa PEG (Supporting Information Figure S2B). As described previously, the 
nitroPBA boronic acid derivative was chosen because of its high binding constant and low pKa 
(ca. 6.8) values with MAP.27,29 As a result, the nitroPBA conjugates form stable boronic acid 
esters with the nanoparticle in circulation, but quickly dissociate from the nanoparticle at pH < 
6.8 to provide ligand detachment during transcytosis.
To assemble TfR-targeted combination CPT/Herceptin nanoparticles, Herceptin-PEG3.5k-
nitroPBA conjugate was added to the MAP-CPT nanoparticles at a 1:1 molar ratio, followed by 
Tf-PEG5k-nitroPBA at a 20 molar excess in PBS, pH 7.4 (Figure 2A). To compare the antitumor 
activity of nanoparticles containing only CPT, Tf-PEG5k-nitroPBA was directly added to the 
MAP-CPT nanoparticles at 20 molar excess (Figure 2B). A Herceptin only nanoparticle control 
was prepared by conjugating a hydrophobic fluorophore (Alexa Fluor 568, AF568) lacking 
antitumor activity to the MAP polymer to promote the formation of nanoparticles upon dialysis 
in water (Supporting Information Figure S3). Herceptin-PEG3.5k-nitroPBA and Tf-PEG5k-
nitroPBA conjugates were added as above to the MAP-AF568 nanoparticles at 1:1 and 20:1 
molar ratios, respectively, to form TfR-targeted Herceptin nanoparticles (Figure 2C). 
Nanoparticles containing Herceptin were purposefully formulated with an average of one 
antibody per nanoparticle. Numerous antibodies can be added to the nanoparticles. However, 
adding just one allowed us to test the “worst-case scenario” for delivering an antibody to the 
brain. If brain delivery and antitumor activity is observed, it is likely that even better efficacy 
will be achievable with nanoparticles containing multiple antibodies.
Nanoparticle diameter and zeta potential measurements were performed on the above 
formulations to verify that the nanoparticles had properties appropriate for transcytosis from 
systemic administrations28,30 as well as diffusion through brain tissue,31 namely a sub-100-nm 
diameter and negative-near-neutral zeta potential. All three nanoparticle formulations had 
diameters between 30-40 nm, as measured by dynamic light scattering, and negative-near-neutral 
zeta potentials when measured in pH 7.4 buffer (Supporting Information Table S2).
The breast cancer brain metastasis model was established by intracardiac (ICD) injection of 
HER2-positive BT474-Gluc cells into Rag2-/-;Il2rg-/- mice. In previous work, we have shown that 
the method used to form brain tumors in mice can dramatically affect the efficacy of therapeutics 
and their brain penetration.27 We observed a marked antitumor response and brain accumulation 
of free CPT, a non-BBB-penetrant small molecule, and a non-targeted nanoparticle containing 
CPT in tumors that were established by stereotaxic intracranial injection. In contrast, treatment 
with the nanoparticles lacking Tf to enable transcytosis gave no antitumor response in both the 
ICD model and a third model we developed involving intravenous injection of the cancer cells 
that more closely replicated the metastasis process in patients. The ICD model, however, did 
allow CPT to penetrate and have a small antitumor effect while our new model did not.  Here, 
the ICD model was chosen because it appears to have an impermeable BBB/BTB to larger 
nanoparticle entities, and will allow comparison to other studies that have employed this method 
of creating brain metastases.
To assess how the incorporation of the therapeutic antibody may affect the efficacy of the 
targeted nanoparticles, we investigated the antitumor activity of TfR-targeted combination 
CPT/Herceptin nanoparticles compared to TfR-targeted CPT nanoparticles, TfR-targeted 
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Herceptin nanoparticles and combined free CPT and Herceptin in the ICD model. A saline 
treatment group was used as the control. Treatment was initiated when tumors reached 2 mm3 in 
volume. Supporting Information Figure S4A shows a representative MRI image of the metastatic 
tumors at the start of treatment. The different formulations were systemically administered 
weekly for 4 weeks at a dose of 4 and/or 24 mg/kg (CPT and/or Herceptin bases, respectively), 
and tumor volume was measured weekly by MRI for 8 weeks. 
Figure 3 shows the results from treating mice bearing brain tumors with the formulations 
described above. Data from individual animals are provided in Supporting Information Figure 
S5. For the physical mixture of CPT and Herceptin, the tumor growth delay is not significantly 
different than previously observed for CPT alone.27 These results suggest that Herceptin is not 
penetrating the BBB/BTB to an extent to produce any antitumor activity, and are consistent with 
data published for Herceptin alone.32 
The tumor growth delay from treatment with TfR-targeted CPT nanoparticles is as we observed 
previously,27 and shows the excellent reproducibility of both the model and the nanoparticle 
synthesis. Compared to previous data demonstrating no tumor growth delay with nanoparticles 
lacking Tf, these results suggest that the antitumor effects observed for this treatment are 
facilitated by targeted nanoparticle delivery of CPT alone. 
TfR-targeted Herceptin nanoparticles give a greater antitumor response than those containing 
CPT, suggesting that the nanoparticles can deliver functional antibodies into the brain via 
transcytosis. It is also encouraging that significant antitumor activity can be achieved when only 
one antibody is on each nanoparticle. Future studies will explore variable amounts of antibody 
contents. 
When both Herceptin and CPT are combined in a TfR-targeted nanoparticle, the best antitumor 
response is observed (compared to the data from Herceptin alone or CPT alone), and the 
antitumor effects appear to be quite durable (final dosing was on week 3). Notably, the type of 
formulation for the combination (free drug vs. nanoparticle) greatly affected the outcome of the 
brain metastases, as shown in Figure 3. MRI images further illustrate the differences between the 
tumors after treatment with the above formulations (Supporting Information Figure S4). These 
results suggest that both the CPT and Herceptin are delivered to the brain via transcytosis of the 
nanoparticle, and indicate that combination therapies will be possible with this type of delivery 
system. 
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Figure 3. Combined nanoparticle delivery of CPT and Herceptin inhibits brain metastatic tumor 
growth more effectively than nanoparticle delivery of either monotherapy and combined free 
drug. Tumor growth curves of BT474-Gluc metastatic brain tumors treated with free CPT and 
Herceptin (gray, 4 and 24 mg/kg, respectively), TfR-targeted CPT nanoparticles (orange, 4 mg 
CPT/kg), TfR-targeted Herceptin nanoparticles containing Alexa Fluor 568 (purple, 24 mg 
Herceptin/kg) and TfR-targeted combination CPT/Herceptin nanoparticles (blue, 4 mg CPT/kg 
and 24 mg Herceptin/kg) compared to saline (black). Data shown are the average of 6 mice per 
treatment group. Error bars indicate SE. P values for pairwise comparisons are provided in the 
Supporting Information, Table S3. NP, nanoparticle. Animals dosed on weeks 0, 1, 2 and 3. 
In summary, TfR-targeted nanoparticles containing either the antibody Herceptin alone or in 
combination with the small molecule drug CPT can deliver their payloads to intracranial breast 
cancer tumors to provide significant antitumor activity. These results not only show that 
functional antibodies can be delivered to the brain, but also that they can be used in combination 
with other drugs to provide enhanced antitumor activity. This initial study was performed with a 
single dose amount and a single dosing schedule. The dosing amount used here is well below 
what is possible with the nanoparticles, and was selected in order to have proper comparison to 
free CPT administered near the maximum tolerated dose. Therefore, further studies with 
increasing dosing amounts and alternative dosing schedules are merited. Importantly, these 
results also open new possibilities for delivering therapeutic combinations to treat brain 
metastases as well as other brain diseases. 
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SI Description.
Detailed experimental procedures, including materials synthesis, nanoparticle formulation, 
antitumor efficacy and statistical analysis.
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